BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Asia PGI Unveils PathGen as a Federated AI Platform for Early Outbreak Intelligence

Asia-led, "sovereign-by-design" platform built for secure, decentralised pathogen intelligence-sharing across borders aims to break data silos and provide ...

December 02, 2025 | News

Generate Plans Global Phase 3 Trials for AI Engineered GB 0895 in Severe Asthma

Generate:Biomedicines ("Generate") announced it plans to initiate two global Phase 3 clinical trials, SOLAIRIA-1 and SOLAIRIA-2, evaluating GB-0895 in appr...

December 02, 2025 | News

Ascletis Advances First Oral Triple Agonist for Obesity, ASC37, into Clinical Development

- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability ...

December 01, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

Zydus and RK Pharma Partner on Innovative Sterile Injectable for Oncology Supportive Care

Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that it has entered into an e...

November 27, 2025 | News

mAIbe and LenioBio Form Strategic Partnership to Accelerate Next-Gen Antibody Discovery

mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation...

November 27, 2025 | News

The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech

Global pharmaceutical companies are racing to tap China’s new AI-powered biotech platforms to discover drugs faster and cheaper. In 2025, major Weste...

November 27, 2025 | Analysis

Accord BioPharma Gains FDA Approval for Two Denosumab Biosimilars to Expand Access to Osteoporosis and Cancer Related Bone Care

Products will treat osteoporosis and skeletal-related events from certain types of bone cancer, expanding the company's biosimilar portfolio Accord BioPha...

November 21, 2025 | News

Hoth Therapeutics Joins NVIDIA Connect Program to Advance AI Driven Drug Discovery

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics announced that it h...

November 21, 2025 | News

Nona Biosciences Enters License Agreement with Pfizer to Advance Global Antibody Discovery

Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea t...

November 20, 2025 | News

Vaxcellbio’s CSO Outlines How DDS Enabled Nanobodies Could Redefine Global Treatment Pathways

Vaxcellbio is betting on the combined power of nanobodies and advanced drug delivery science to push boundaries across ophthalmology and other chronic dise...

November 20, 2025 | Interaction

AbbVie Secures Approval for EPKINLY in Combination With R2 as the First Bispecific Therapy for Relapsed or Refractory Follicular Lymphoma

EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available f...

November 19, 2025 | News

Celltrion Gains EU Approval for Omlyclo 300 mg Prefilled Syringe as First Omalizumab Biosimilar

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) presentat...

November 19, 2025 | News

Lundbeck Moves Closer to Asian Launch of Vyepti with New Drug Application Accepted in Japan

Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), mark...

November 17, 2025 | News

Stay Connected